Kolon, Mitsubishi Tanabe Deal

Kolon granted Mitsubishi exclusive, Japanese rights to develop and commercialize Invossa, which is in development to treat osteoarthritis (OA) of the knee. Kolon will receive ¥2.5 billion ($23.8 million) up front and is eligible for up to ¥43.2 billion ($410.4 million) in milestones, plus double-digit royalties...